Source:http://linkedlifedata.com/resource/pubmed/id/12750298
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2003-5-16
|
pubmed:abstractText |
A 2-year old boy was diagnosed with Fanconi anemia (FA) and acute myeloid leukemia (AML). A cell line (termed FA-AML1) was established from blast cells obtained after a second relapse after a successful bone marrow transplant. Histochemical and surface marker analysis confirmed that the cells were derived from the myeloid lineage. Cytogenetic analysis revealed multiple chromosomal aberrations, including a ring 7. Stable proliferation of the cultured cells was absolutely dependent on the presence of granulocyte macrophage colony-stimulating factor or interleukin 3. This is the first AML cell line successfully established from a FA patient. Remarkably, FA-AML1 cells appeared to lack the characteristic cellular FA phenotype, i.e., a hypersensitivity to growth inhibition and chromosomal breakage by the cross-linking agent mitomycin C. Genomic DNA from the patient showed biallelic mutations [8415G>T (K2729N)and 8732C>A (S2835STOP)] in the breast cancer susceptibility gene FANCD1/BRCA2 [N. Howlett et al., Science (Wash. DC), 297: 606-609, 2002]. In the AML cells, however, the 8732C>A nonsense mutation was changed into a missense mutation by a secondary alteration, 8731T>G, resulting in 2835E, which restored the open-reading frame of the gene and could explain the reverted phenotype of these cells. Loss of the FA phenotype by genetic correction of a FA gene mutation during AML progression may be a common late event in the pathogenesis of AML in FA patients, which may be treatment related. This finding suggests a novel mechanistic principle of tumor progression based on the genetic correction of an early caretaker gene defect.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0008-5472
|
pubmed:author |
pubmed-author:D'AndreaAlan DAD,
pubmed-author:De WinterJohan PJP,
pubmed-author:HoatlinMaureen EME,
pubmed-author:IkedaHideyukiH,
pubmed-author:JoenjeHansH,
pubmed-author:KawaiYohkoY,
pubmed-author:KawakamiYutakaY,
pubmed-author:KinoshitaAkitoshiA,
pubmed-author:MatsushitaMaikoM,
pubmed-author:NieuwintAggie W MAW,
pubmed-author:OostraAnneke BAB,
pubmed-author:SasakiMasao SMS,
pubmed-author:WaisfiszQuintenQ
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
63
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2688-94
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12750298-Alleles,
pubmed-meshheading:12750298-Antigens, CD,
pubmed-meshheading:12750298-Cell Division,
pubmed-meshheading:12750298-Child, Preschool,
pubmed-meshheading:12750298-Fanconi Anemia,
pubmed-meshheading:12750298-Genes, BRCA2,
pubmed-meshheading:12750298-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:12750298-Humans,
pubmed-meshheading:12750298-Interleukin-3,
pubmed-meshheading:12750298-Karyotyping,
pubmed-meshheading:12750298-Leukemia, Myeloid, Acute,
pubmed-meshheading:12750298-Male,
pubmed-meshheading:12750298-Mutation,
pubmed-meshheading:12750298-Tumor Cells, Cultured
|
pubmed:year |
2003
|
pubmed:articleTitle |
Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.
|
pubmed:affiliation |
Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo 160-8582, Japan.
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|